SCHEMBL650238

SCHEMBL650238

CCCCn1c(-c2ccccc2)nc(-c2cccc(F)c2)c1CN(Cc1ccc(OC(F)F)cc1)Cc1ccc(OC(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TSHR P16473 2/20 0.35
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
LTB4R2 Q9NPC1 2/20 0.34
MMP13 P45452 2/20 0.34
BACE1 P56817 2/20 0.34
PDE4B Q07343 2/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2B Q13224 1/20 0.33
LMNA P02545 1/20 0.33
TLR8 Q9NR97 1/20 0.33
MDM2 Q00987 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650506 0.93 C5AR1 (0.37) C5AR1MEN1KMT2AALDH1A1HTT
SCHEMBL648894 0.92 TP53 (0.40) C5AR1MEN1KMT2ATSHRALDH1A1
SCHEMBL651033 0.92 C5AR1 (0.44) C5AR1TSHRALDH1A1HTTMMP13
SCHEMBL649675 0.91 C5AR1 (0.42) C5AR1TSHRALDH1A1HTTMMP13
SCHEMBL650574 0.91 C5AR1 (0.41) C5AR1TSHRALDH1A1HTTMMP13
SCHEMBL651956 0.91 C5AR1 (0.43) C5AR1TSHRALDH1A1HTTMMP13
SCHEMBL652169 0.91 C5AR1 (0.55) C5AR1TSHRALDH1A1LMNA
SCHEMBL653383 0.91 C5AR1 (0.39) C5AR1MEN1KMT2ATSHRALDH1A1
SCHEMBL647750 0.91 C5AR1 (0.39) C5AR1TSHRALDH1A1HTTLTB4R2
SCHEMBL648415 0.91 TLR7 (0.40) C5AR1MEN1KMT2APDE4BTLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed